331 related articles for article (PubMed ID: 15703409)
1. Transgenic expression of human connexin32 in myelinating Schwann cells prevents demyelination in connexin32-null mice.
Scherer SS; Xu YT; Messing A; Willecke K; Fischbeck KH; Jeng LJ
J Neurosci; 2005 Feb; 25(6):1550-9. PubMed ID: 15703409
[TBL] [Abstract][Full Text] [Related]
2. Prenylation-defective human connexin32 mutants are normally localized and function equivalently to wild-type connexin32 in myelinating Schwann cells.
Huang Y; Sirkowski EE; Stickney JT; Scherer SS
J Neurosci; 2005 Aug; 25(31):7111-20. PubMed ID: 16079393
[TBL] [Abstract][Full Text] [Related]
3. The effects of a dominant connexin32 mutant in myelinating Schwann cells.
Jeng LJ; Balice-Gordon RJ; Messing A; Fischbeck KH; Scherer SS
Mol Cell Neurosci; 2006 Jul; 32(3):283-98. PubMed ID: 16790356
[TBL] [Abstract][Full Text] [Related]
4. Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease.
Sargiannidou I; Kagiava A; Bashiardes S; Richter J; Christodoulou C; Scherer SS; Kleopa KA
Ann Neurol; 2015 Aug; 78(2):303-16. PubMed ID: 26010264
[TBL] [Abstract][Full Text] [Related]
5. Intrathecal gene therapy in mouse models expressing CMT1X mutations.
Kagiava A; Karaiskos C; Richter J; Tryfonos C; Lapathitis G; Sargiannidou I; Christodoulou C; Kleopa KA
Hum Mol Genet; 2018 Apr; 27(8):1460-1473. PubMed ID: 29462293
[TBL] [Abstract][Full Text] [Related]
6. Golgi-retained Cx32 mutants interfere with gene addition therapy for CMT1X.
Kyriakoudi S; Sargiannidou I; Kagiava A; Olympiou M; Kleopa KA
Hum Mol Genet; 2017 May; 26(9):1622-1633. PubMed ID: 28334782
[TBL] [Abstract][Full Text] [Related]
7. How do mutations in GJB1 cause X-linked Charcot-Marie-Tooth disease?
Kleopa KA; Abrams CK; Scherer SS
Brain Res; 2012 Dec; 1487():198-205. PubMed ID: 22771394
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetics of X-linked Charcot-Marie-Tooth disease.
Kleopa KA; Scherer SS
Neuromolecular Med; 2006; 8(1-2):107-22. PubMed ID: 16775370
[TBL] [Abstract][Full Text] [Related]
9. Genetic epidemiology of Charcot-Marie-Tooth disease.
Braathen GJ
Acta Neurol Scand Suppl; 2012; (193):iv-22. PubMed ID: 23106488
[TBL] [Abstract][Full Text] [Related]
10. Connexin32 and X-linked Charcot-Marie-Tooth disease.
Bone LJ; Deschênes SM; Balice-Gordon RJ; Fischbeck KH; Scherer SS
Neurobiol Dis; 1997; 4(3-4):221-30. PubMed ID: 9361298
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling studies in regenerating nerves in a mouse model for CMT1X: uninjured Cx32-knockout peripheral nerves display expression profile of injured wild type nerves.
Freidin M; Asche-Godin S; Abrams CK
Exp Neurol; 2015 Jan; 263():339-49. PubMed ID: 25447941
[TBL] [Abstract][Full Text] [Related]
12. Connexin32-null mice develop demyelinating peripheral neuropathy.
Scherer SS; Xu YT; Nelles E; Fischbeck K; Willecke K; Bone LJ
Glia; 1998 Sep; 24(1):8-20. PubMed ID: 9700485
[TBL] [Abstract][Full Text] [Related]
13. Altered gene expression in Schwann cells of connexin32 knockout animals.
Nicholson SM; Gomès D; de Néchaud B; Bruzzone R
J Neurosci Res; 2001 Oct; 66(1):23-36. PubMed ID: 11598999
[TBL] [Abstract][Full Text] [Related]
14. AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy.
Kagiava A; Karaiskos C; Richter J; Tryfonos C; Jennings MJ; Heslegrave AJ; Sargiannidou I; Stavrou M; Zetterberg H; Reilly MM; Christodoulou C; Horvath R; Kleopa KA
Gene Ther; 2021 Nov; 28(10-11):659-675. PubMed ID: 33692503
[TBL] [Abstract][Full Text] [Related]
15. Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X.
Kagiava A; Richter J; Tryfonos C; Karaiskos C; Heslegrave AJ; Sargiannidou I; Rossor AM; Zetterberg H; Reilly MM; Christodoulou C; Kleopa KA
Hum Mol Genet; 2019 Nov; 28(21):3528-3542. PubMed ID: 31411673
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis of X-linked Charcot-Marie-Tooth disease: differential effects of two mutations in connexin 32.
Abrams CK; Freidin M; Bukauskas F; Dobrenis K; Bargiello TA; Verselis VK; Bennett MV; Chen L; Sahenk Z
J Neurosci; 2003 Nov; 23(33):10548-58. PubMed ID: 14627639
[TBL] [Abstract][Full Text] [Related]
17. Connexin channels in Schwann cells and the development of the X-linked form of Charcot-Marie-Tooth disease.
Ressot C; Bruzzone R
Brain Res Brain Res Rev; 2000 Apr; 32(1):192-202. PubMed ID: 10751670
[TBL] [Abstract][Full Text] [Related]
18. Axonal pathology precedes demyelination in a mouse model of X-linked demyelinating/type I Charcot-Marie Tooth neuropathy.
Vavlitou N; Sargiannidou I; Markoullis K; Kyriacou K; Scherer SS; Kleopa KA
J Neuropathol Exp Neurol; 2010 Sep; 69(9):945-58. PubMed ID: 20720503
[TBL] [Abstract][Full Text] [Related]
19. Connexins, gap junctions and peripheral neuropathy.
Kleopa KA; Sargiannidou I
Neurosci Lett; 2015 Jun; 596():27-32. PubMed ID: 25449862
[TBL] [Abstract][Full Text] [Related]
20. Studies in transgenic mice indicate a loss of connexin32 function in X-linked Charcot-Marie-Tooth disease.
Abel A; Bone LJ; Messing A; Scherer SS; Fischbeck KH
J Neuropathol Exp Neurol; 1999 Jul; 58(7):702-10. PubMed ID: 10411340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
